VolitionRX (NYSEAMERICAN:VNRX) will post its quarterly earnings results after the market closes on Monday, August 12th. Analysts expect VolitionRX to post earnings of ($0.12) per share for the quarter.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Wednesday, May 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12).

VolitionRX stock opened at $3.86 on Friday. VolitionRX has a 1 year low of $1.67 and a 1 year high of $4.65.

In other VolitionRX news, Director Martin Charles Faulkes acquired 70,731 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was bought at an average cost of $3.02 per share, for a total transaction of $213,607.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Read More: What is a Real Estate Investment Trust (REIT)?

Earnings History for VolitionRX (NYSEAMERICAN:VNRX)

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.